Avalo Therapeutics Inc AVTX 深 沪
交易中 03-25 10:16:13 美东时间
14.23
+0.780
+5.80%
华盛通- 最 高14.5494
- 今 开14.26
- 成交量 8.17万股
- 最 低 14.105
- 昨 收 13.45
- 总市值 2.63亿
- 52周最高 20.7199
- 市盈率 静 --
- 换手率 0.44%
- 52周最低 3.39
- 委 比 33.33%
- 总股本 1851.28万
- 历史最高 22032.00
- 量 比 0.99
- 振 幅 3.30%
- 历史最低 3.39
- 每 手 1
- 风险率 5.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
今天 10:31
BTIG Reiterates Buy on Avalo Therapeutics, Maintains $40 Price Target
BTIG analyst Julian Harrison reiterates Avalo Therapeutics (NASDAQ:AVTX) with a Buy and maintains $40 price target.
03-24 17:57
Avalo Therapeutics Publishes Corporate Presentation on Abdakibart IL-1β Therapy for Hidradenitis Suppurativa
Avalo Therapeutics Publishes Corporate Presentation on Abdakibart IL-1β Therapy for Hidradenitis Suppurativa Avalo outlined its focus on developing IL-1β therapies for immune-mediated inflammatory diseases, with abdakibart (AVTX-009) as its lead anti-IL-1β monoclonal antibody. The company said enrol
03-23 19:34
Avalo Therapeutics posts lower-than-expected 2025 net loss
Avalo Therapeutics posts lower-than-expected 2025 net loss Overview U.S. IL-1β drug developer's 2025 net loss is lower than expected Operating expenses rose due to increased R&D for Phase 2 LOTUS trial Outlook Company expects cash and investments at Dec 31, 2025, to fund operations into 2028 Result
03-23 19:12
Earnings Scheduled For March 23, 2026
Companies Reporting Before The Bell • Avalo Therapeutics (NASDAQ:AVTX) is likel...
03-23 19:11
Avalo Therapeutics Q4 EPS $(0.48) Beats $(1.47) Estimate, Sales $59.000K Down From $192.000K YoY
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(1.47) by 67.3 percent. This is a 127.91 percent decrease over earnings of $1.72 per share
03-23 19:10
Avalo Therapeutics FY2025 net loss widens 123% to USD 78 million, R&D expenses rise 105% to USD 50 million
Avalo Therapeutics FY2025 net loss widens 123% to USD 78 million, R&D expenses rise 105% to USD 50 million Avalo published a full-year earnings release reporting a net loss of USD 78.3 million and a loss from operations of USD 72.9 million. Revenue was USD 59,000 and interest income, net was USD 4.4
03-23 19:01
Avalo Therapeutics Grants 82,000 Inducement Stock Options to New Employees
Avalo Therapeutics Grants 82,000 Inducement Stock Options to New Employees Avalo Therapeutics granted two new employees nonstatutory stock options covering a total of 82,000 shares, with an exercise price of $14.26 per share. The options vest 25% on the one-year anniversary of each employee’s start
02-19 05:05
美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
Guggenheim Initiates Coverage On Avalo Therapeutics with Buy Rating, Announces Price Target of $50
Guggenheim analyst Yatin Suneja initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and announces Price Target of $50.
02-02 22:23
